The Pfizer-Seagen takeover opens up a window of opportunity for long-dated U.S. Treasuries The Pfizer-Seagen takeover opens up a window of opportunity for long-dated U.S. Treasuries The Pfizer-Seagen takeover opens up a window of opportunity for long-dated U.S. Treasuries

The Pfizer-Seagen takeover opens up a window of opportunity for long-dated U.S. Treasuries

Bonds
Althea Spinozzi

Head of Fixed Income Strategy

Summary:  The Pfizer-Seagen deal is likely to have caused the sudden rise of long-term U.S. Treasury yields above a critical resistance level. Thirty-year yields now look headed to 4% as they have broken bullish out of the symmetrical triangle-like pattern it has formed in the past couple of months. Today's 20-year U.S. Treasury auction, tomorrow's initial jobless claims, and the Philadelphia Fed business outlook might further contribute to their rise. Nevertheless, in the long term, the upside for long-term yields is limited, as they are poised to retrace while the economy decelerates.


While 2, 5, and 10-year U.S. Treasury yields are range bound, the 30-year Treasury yield has broken bullish out of the symmetrical triangle-like pattern it has formed over the past few months. They now look headed for resistance at around 4%. If breaking above the March peak at about 4.025%, there is potential for an October peak at about 4.40%. A move below 3.67% will demolish and reverse this bullish scenario (courtesy of Kim Cramer Larsson, Technical Analyst).

Source: Saxo Platform and Kim Cramer, Technical Analyst

It’s important to note that long-term yields began to rise on Monday when rumors of a Pfizer-Seagen deal started to spread. By raising $31 billion, the Pfizer-Seagen deal became the fourth-largest deal in U.S. capital markets. For investors, it meant that bonds of a high-quality, non-cyclical company with a rating of A1/A+ would provide an alternative to U.S. Treasuries. That is particularly true on the long part of the yield curve, where yields remain compressed amid recessionary fears. The 40-year tranche was the highlight of the deal, pricing at 160bps over treasuries, down from 180bps IPT due to high demand. Consequently, investors sold Treasuries to make space in their portfolios to participate in the deal.

As Kim noted above, 30-year yields seem now headed towards 4%. Today's 20-year U.S. Treasury auction might help yields to rise further towards this level, as it remains one the least liked maturities across the yield curve. Tomorrow’s initial jobless claims and the Philadelphia Fed business outlook might also affect long-term yields.

Yet, the upside for long-term yields remains limited, as they are poised to retrace as the economy decelerates, consumer sentiment is weak, and credit tightening leads the economy into a recession.

What instruments should I use to get exposure to long-term U.S. Treasuries?

  • 30YK3 is the Micro 30-year yield future contract expiring on May 31st, 2023. This future provides traders with an efficient way to trade U.S. Treasury yields. The contract will rise when Treasury yields increase and fall when they decline. Thus, there is no need to look at the inverse relationship between yield and price. CME also offers the same product for the following key tenors: 2-year (2YY), 5-year and 10-year Notes (10Y).

  •  30-year U.S. Treasury Bond futures contract (ZB).

  • 30YUSTBOND is the CFD on the U.S. Treasury Bond future contract.

  • TLT is the iShares Barclays 20+ Year Treasury Bond Fund which gives exposure to the longer part of the yield curve.

Disclaimer

The Saxo Group entities each provide execution-only service, and access to analysis permitting a person to view and/or use content available on or via the website is not intended to and does not change or expand on this. Such access and use are at all times subject to (i) The Terms of Use; (ii) Full Disclaimer; (iii) The Risk Warning; (iv) the Inspiration Disclaimer and (v) Notices applying to Trade Inspiration, Saxo News & Research and/or its content in addition (where relevant) to the terms governing the use of hyperlinks on the website of a member of the Saxo Group by which access to Saxo News & Research is gained. Such content is therefore provided as no more than information. In particular, no advice is intended to be provided or to be relied on as provided nor endorsed by any Saxo Group entity; nor is it to be construed as solicitation or an incentive provided to subscribe for or sell or purchase any financial instrument. All trading or investments you make must be pursuant to your own unprompted and informed self-directed decision. As such no Saxo Group entity will have or be liable for any losses that you may sustain as a result of any investment decision made in reliance on information which is available on Saxo News & Research or as a result of the use of the Saxo News & Research. Orders given and trades effected are deemed intended to be given or effected for the account of the customer with the Saxo Group entity operating in the jurisdiction in which the customer resides and/or with whom the customer opened and maintains his/her trading account. Saxo News & Research does not contain (and should not be construed as containing) financial, investment, tax or trading advice or advice of any sort offered, recommended or endorsed by Saxo Group and should not be construed as a record of our trading prices, or as an offer, incentive or solicitation for the subscription, sale or purchase in any financial instrument. To the extent that any content is construed as investment research, you must note and accept that the content was not intended to and has not been prepared in accordance with legal requirements designed to promote the independence of investment research and as such, would be considered as a marketing communication under relevant laws.

Trading in financial instruments carries risk, and may not be suitable for you. Past performance is not indicative of future performance. Please read our disclaimers:
Notification on Non-Independent Investment Research (https://www.home.saxo/legal/niird/notification)
Full disclaimer (https://www.home.saxo/en-sg/legal/disclaimer/saxo-disclaimer)

None of the information contained here constitutes an offer to purchase or sell a financial instrument, or to make any investments. Saxo Markets does not take into account your personal investment objectives or financial situation and makes no representation and assumes no liability as to the accuracy or completeness of the information nor for any loss arising from any investment made in reliance of this presentation. Any opinions made are subject to change and may be personal to the author. These may not necessarily reflect the opinion of Saxo Markets or its affiliates.

Saxo Markets
88 Market Street
CapitaSpring #31-01
Singapore 048948

Contact Saxo

Select region

Singapore
Singapore

Saxo Capital Markets Pte Ltd ('Saxo Markets') is a company authorised and regulated by the Monetary Authority of Singapore (MAS) [Co. Reg. No.: 200601141M ] and is a wholly owned subsidiary of Saxo Bank A/S, headquartered in Denmark. Please refer to our General Business Terms & Risk Warning to consider whether acquiring or continuing to hold financial products is suitable for you, prior to opening an account and investing in a financial product.

Trading in financial instruments carries various risks, and is not suitable for all investors. Please seek expert advice, and always ensure that you fully understand these risks before trading. Trading in leveraged products such as Margin FX products may result in your losses exceeding your initial deposits. Saxo Markets does not provide financial advice, any information available on this website is ‘general’ in nature and for informational purposes only. Saxo Markets does not take into account an individual’s needs, objectives or financial situation.

The Saxo trading platform has received numerous awards and recognition. For details of these awards and information on awards visit www.home.saxo/en-sg/about-us/awards.

The information or the products and services referred to on this website may be accessed worldwide, however is only intended for distribution to and use by recipients located in countries where such use does not constitute a violation of applicable legislation or regulations. Products and Services offered on this website are not intended for residents of the United States, Malaysia and Japan. Please click here to view our full disclaimer.

This advertisement has not been reviewed by the Monetary Authority of Singapore.

Apple and the Apple logo are trademarks of Apple Inc, registered in the US and other countries and regions. App Store is a service mark of Apple Inc. Google Play and the Google Play logo are trademarks of Google LLC.